PTC Therapeutics director sells $149,036 in shares

PTC Therapeutics' director Michael Schmertzler sold 2,500 shares of the company's common stock on October 14, 2026, according to an SEC Form 4 filing. The sale, executed under a Rule 10b5-1 trading plan, totaled $149,036 with share prices fluctuating between $59.52 and $60.14. Schmertzler, a general and limited partner of Section Six Partners, L.P., which owned the shares, sold 2,118 shares at an average price of $59.52 and 382 shares at an average price of $60.14.

This left Section Six Partners with 1,291,594 shares of PTC Therapeutics stock. The insider sale occurred as PTCT shares approached a 52-week low of $58.80, experiencing a 22% decline year-to-date. Despite the company's current unprofitability, analysts anticipate profitability in the upcoming year. PTCT reported strong earnings in Q2 2026, exceeding expectations with $0.92 per share in earnings per share and $361 million in revenue.

The company's acquisition of ST-920 from Sangamo and a raised price target from Cantor Fitzgerald contributed to this success. PTC Therapeutics remains well-positioned for growth with $2.23 billion in cash reserves.